Alessia Piluso1, Laura Gragnani2, Elisa Fognani3, Elena Grandini4, Monica Monti5, Cristina Stasi6, Elisabetta Loggi7, Marzia Margotti8, Fabio Conti9, Pietro Andreone10, Anna Linda Zignego11. 1. Department of Experimental and Clinical Medicine, Center for Systemic Manifestations of Hepatitis Viruses (MASVE), University of Florence, Largo Brambilla 3, 50134, Florence, Italy. alepilu80@libero.it. 2. Department of Experimental and Clinical Medicine, Center for Systemic Manifestations of Hepatitis Viruses (MASVE), University of Florence, Largo Brambilla 3, 50134, Florence, Italy. laura.gragnani@unifi.it. 3. Department of Experimental and Clinical Medicine, Center for Systemic Manifestations of Hepatitis Viruses (MASVE), University of Florence, Largo Brambilla 3, 50134, Florence, Italy. elisa.fognani@gmail.com. 4. Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. elena.grandini2@unibo.it. 5. Department of Experimental and Clinical Medicine, Center for Systemic Manifestations of Hepatitis Viruses (MASVE), University of Florence, Largo Brambilla 3, 50134, Florence, Italy. monica.monti@unifi.it. 6. Department of Experimental and Clinical Medicine, Center for Systemic Manifestations of Hepatitis Viruses (MASVE), University of Florence, Largo Brambilla 3, 50134, Florence, Italy. cristina.stasi@unifi.it. 7. Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. elisabetta.loggi@unibo.it. 8. Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. marzia.margotti2@unibo.it. 9. Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. fabio.conti2@studio.unibo.it. 10. Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. pietro.andreone@unibo.it. 11. Department of Experimental and Clinical Medicine, Center for Systemic Manifestations of Hepatitis Viruses (MASVE), University of Florence, Largo Brambilla 3, 50134, Florence, Italy. a.zignego@dmi.unifi.it.
Abstract
BACKGROUND AND AIM: Hepatocellular carcinoma is one of the major causes of death due to cancer worldwide, and its association with hepatitis C virus infection has been definitively established. Hepatitis C virus is also involved in the pathogenesis of non-Hodgkin's lymphoma. This is the only virus infecting humans that is able to induce two different malignancies. We analyzed the expression levels of a panel of microRNA in peripheral blood mononuclear cells of patients with hepatitis C virus-related malignancies in order to find a disease-associated deregulation and identify specific biomarkers. METHODS: We tested peripheral blood mononuclear cells isolated from patients with hepatocellular carcinoma, non-Hodgkin's lymphoma, hepatitis C virus without malignancies and healthy subjects for a panel of microRNA selected on the basis of previous studies. MicroRNA expression was evaluated by real-time PCR. RESULTS: Our results showed an upregulation of miRNA-21 and downregulation of miRNA-26b in hepatocellular carcinoma and non-Hodgkin's lymphoma patients compared to controls (p < 0.001). Deregulation of miRNA-16 and miRNA-155 was limited to lymphoma patients. CONCLUSIONS: This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus, analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers.
BACKGROUND AND AIM: Hepatocellular carcinoma is one of the major causes of death due to cancer worldwide, and its association with hepatitis C virus infection has been definitively established. Hepatitis C virus is also involved in the pathogenesis of non-Hodgkin's lymphoma. This is the only virus infecting humans that is able to induce two different malignancies. We analyzed the expression levels of a panel of microRNA in peripheral blood mononuclear cells of patients with hepatitis C virus-related malignancies in order to find a disease-associated deregulation and identify specific biomarkers. METHODS: We tested peripheral blood mononuclear cells isolated from patients with hepatocellular carcinoma, non-Hodgkin's lymphoma, hepatitis C virus without malignancies and healthy subjects for a panel of microRNA selected on the basis of previous studies. MicroRNA expression was evaluated by real-time PCR. RESULTS: Our results showed an upregulation of miRNA-21 and downregulation of miRNA-26b in hepatocellular carcinoma and non-Hodgkin's lymphomapatients compared to controls (p < 0.001). Deregulation of miRNA-16 and miRNA-155 was limited to lymphomapatients. CONCLUSIONS: This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C viruspatients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus, analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers.
Entities:
Keywords:
Biomarker; Hepatitis C virus; Hepatocellular carcinoma; Non-Hodgkin’s lymphoma; microRNA
Authors: Lorena Di Lisio; Nerea Martinez; Santiago Montes-Moreno; Miguel Piris-Villaespesa; Margarita Sanchez-Beato; Miguel A Piris Journal: Blood Date: 2012-07-03 Impact factor: 22.113
Authors: Martyna Grek; Anna Piekarska; Jacek Bartkowiak; Wojciech Fendler; Jan Kuydowicz; Piotr Wroblewski; Marek Paradowski; Malgorzata Sidorkiewicz Journal: Int J Mol Med Date: 2011-07-12 Impact factor: 4.101
Authors: Laura Gramantieri; Manuela Ferracin; Francesca Fornari; Angelo Veronese; Silvia Sabbioni; Chang-Gong Liu; George A Calin; Catia Giovannini; Eros Ferrazzi; Gian Luca Grazi; Carlo M Croce; Luigi Bolondi; Massimo Negrini Journal: Cancer Res Date: 2007-07-01 Impact factor: 12.701
Authors: N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter Journal: Blood Date: 1994-09-01 Impact factor: 22.113
Authors: Ewa Paszkiewicz-Kozik; Agnieszka Paziewska; Maria Kulecka; Michalina Dąbrowska; Anna Kluska; Aneta Bałabas; Magdalena Piątkowska; Filip Ambrożkiewicz; Joanna Tajer; Włodzimierz Osiadacz; Joanna Romejko-Jarosińska; Martyna Kotarska; Natalia Żeber-Lubecka; Jakub Karczmarski; Lidia Popławska; Michał Mikula; Piotr Rutkowski; Jan Walewski; Jerzy Ostrowski Journal: Biomed Res Int Date: 2021-02-04 Impact factor: 3.411